No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SRPT Sarepta Therapeutics
- 130.285
- -5.755-4.23%
Trading May 8 13:22 ET
12.32BMarket Cap302.99P/E (TTM)
137.140High129.470Low749.72KVolume137.140Open136.040Pre Close99.19MTurnover0.83%Turnover RatioLossP/E (Static)94.52MShares159.89052wk High12.81P/B11.77BFloat Cap55.25052wk Low--Dividend TTM90.36MShs Float181.830Historical High--Div YieldTTM5.64%Amplitude2.598Historical Low132.302Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Boy Given Pfizer Experimental Duchenne Muscular Dystrophy Therapy Dies
Express News | Sarepta Therapeutics Shares Move Higher; Traders Circulate STAT News Report 'Young Boy Dies in Trial for Pfizer Duchenne Gene Therapy.' BZ NOTE: Co Makes Competing DMD Drug
Express News | Sarepta Therapeutics Inc : Guggenheim Raises Target Price to $148 From $145
Sarepta Therapeutics(SRPT.US) Officer Sells US$508.9K in Common Stock
$Sarepta Therapeutics(SRPT.US)$ Officer Murray Dallan sold 3,635 shares of common stock on May 2, 2024 at an average price of $140 for a total value of $508.9K.Source: Announcement(one of the forms) W
Express News | Sarepta Therapeutics Inc : Evercore ISI Raises Target Price to $139 From $138
Express News | JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $175
Comments
Analysts see the shortened timeline and absence of an advisory committee meeting as positive signs for unrestricted approval. The FDA's eagerness to expand the label and transition from accelerated to traditional approval is evident in the expedited review timeline. This could set a precedent for other gene therapies seeking FDA approval, despite Elevidys not meeting its primary endpoint.
1
Sarepta Therapeutics' low P/S ratio reflects its poor revenue outlook. The market anticipates limited growth, hence the reduced stock price. Even a recent share price surge couldn't bring the P/S to industry median. A strong share price rise seems unlikely under these conditions.
Morning Movers
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
17
The promise for a bright 2024 comes after two years of abysmal performance of biopharma stocks. The S&P Biotechnology Select Industry Index surged 43% from its recent low in October 2023, reaching a new high since April 2022.
Source: S&P
A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...
Source: S&P
A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...
8
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg